Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
RecruitingNCT07159750
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
The goal of this observational study is to evaluate clinical differences in patients who received preventive treatment with medication targeting calcitonin gene-related peptide (CGRP) or its receptor: monoclonal antibodies (erenumab, galcanezumab, fremanezumab, eptinezumab) or gepants (rimegepant, atogepant) during a 2-year period observation phase.
Study details
- Official title
- Real-world Prospective Study on the Use of Anti-CGRP Drugs in Migraine
- Conditions
- Migraine
- Episodic Migraine
- Chronic Migraine, Headache
- Interventions
- Drug: CGRP antibody or gepant
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
- Start date
- 2024-01-02
- Primary completion
- 2026-01
- Sex
- All
- Age range
- from 18 Years
- Results posted
- No results posted in this snapshot
- Countries
- Argentina, Chile, Colombia, Croatia, Germany, Italy, Malaysia, Norway, Poland, Portugal, Spain, Turkey (Türkiye), United States
- Total sites listed
- 26
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Migraine diagnosis according to ICHD-III. * Prescription of erenumab, galcanezumab, fremanezumab, eptinezumab, atogepant or rimegepant according to prescriptor criteria and reimbursement criteria according to local regulations. * Signature of informed consent. Exclusion Criteria: * Presence of headache different from migraine. * Active severe psychiatric condition or cognitive impairment which may affect the ability to consent patient's participation in the study.
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT07159750